Study Title: A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
For more information about the trial above please contact the study team:Medical University of South CarolinaPrincipal Investigator, Orr, Brian, at orrb@musc.edu.Study Coordinator, Knox, Crystal, at knoxc@musc.edu.Trial opened at the following institutions: Medical University of South Carolina